Moderna, Inc. (MRNA): Capital Expenditures
$192.00M
Year ended 2025-12-31
$171.00M
Trailing 12 months to 2026-06-30
-21.7%
3-year compound annual growth
+23.1%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $192.00M | -81.7% | 2026-02-20, From 2025-01-01 |
| 2024-12-31 | $1.05B | +48.7% | 2026-02-20, From 2024-01-01 |
| 2023-12-31 | $707.00M | +76.8% | 2026-02-20, From 2023-01-01 |
| 2022-12-31 | $400.00M | +40.8% | 2025-02-21, From 2022-01-01 |
| 2021-12-31 | $284.00M | +317.6% | 2024-02-23, From 2021-01-01 |
| 2020-12-31 | $68.00M | +112.5% | 2023-02-24, From 2020-01-01 |
| 2019-12-31 | $32.00M | n/c | 2022-02-25, From 2019-01-01 |
| 2018-12-31 | $105.77M | +81.1% | 2021-02-26, From 2018-01-01 |
| 2017-12-31 | $58.40M | +76.2% | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $33.14M | n/a | 2019-03-13, From 2016-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Moderna, Inc. (MRNA) | 2025-12-31 | $192.00M | -81.7% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $201.05M | +20.3% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $8.43M | -70.4% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $6.97M | -34.8% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $34.00M | -11.0% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $28.85M | -7.0% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $2.47M | +119.6% |
| Repligen Corp (RGEN) | 2025-12-31 | $23.52M | -8.4% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $22.57M | +174.4% |
Compare MRNA, QGEN, EXEL, HALO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗